Mangoceuticals Stock Surges On Early Success Of Subscription TRT Model

Mangoceuticals, Inc. (NASDAQ:MGRX) shares are trading higher due to the early success of its new all-inclusive injectable Testosterone Replacement Therapy (TRT) treatment program. The company reported a 336% increase in month-over-month sales for its TRT program since mid-December and a 54% reduction in customer acquisition costs. This $99-per-month program, delivered via telehealth, is expected to be Mangoceuticals’ primary growth driver.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.
  • Reward
  • Comment
  • Repost
  • Share
Comment
0/400
No comments
  • Pin

Trade Crypto Anywhere Anytime
qrCode
Scan to download Gate App
Community
  • 简体中文
  • English
  • Tiếng Việt
  • 繁體中文
  • Español
  • Русский
  • Français (Afrique)
  • Português (Portugal)
  • Bahasa Indonesia
  • 日本語
  • بالعربية
  • Українська
  • Português (Brasil)